News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
822,655 Results
Type
Article (85152)
Company Profile (621)
Press Release (736882)
Section
Business (231563)
Career Advice (4090)
Deals (39618)
Drug Delivery (106)
Drug Development (90348)
Employer Resources (192)
FDA (17839)
Job Trends (17242)
News (394128)
Policy (39558)
Tag
Academia (2970)
Africa (1259)
Alliances (56281)
Alzheimer's disease (1232)
Approvals (17770)
Arizona (200)
Artificial intelligence (72)
Asia (48907)
Australia (8605)
Bankruptcy (392)
Best Places to Work (12206)
Biosimilars (71)
Biotechnology (437)
C2C Services and Suppliers (95129)
California (1723)
Canada (804)
Cancer (449)
Career advice (3497)
Cell therapy (136)
China (129)
Clinical research (70280)
Collaboration (127)
Compensation (68)
Connecticut (63)
COVID-19 (2742)
Cystic fibrosis (75)
Data (248)
Diabetes (66)
Diagnostics (6465)
Drug pricing (64)
Earnings (93179)
Employer resources (162)
Europe (111807)
Events (124664)
Executive appointments (125)
FDA (17984)
Florida (201)
Funding (124)
Gene therapy (100)
GLP-1 (580)
Government (4990)
Healthcare (20586)
Hotbed/Location (534624)
Illinois (276)
Indiana (142)
Infectious disease (2762)
Inflammatory bowel disease (100)
Interviews (805)
IPO (17450)
Job creations (5172)
Job search strategy (2849)
Kansas (100)
Layoffs (463)
Legal (9998)
Lung cancer (105)
Manufacturing (86)
Maryland (396)
Massachusetts (1542)
Medical device (14185)
Medtech (14190)
Mergers & acquisitions (21916)
Metabolic disorders (241)
Michigan (118)
Minnesota (207)
Neuroscience (1377)
New Jersey (530)
New York (524)
NextGen Class of 2024 (7621)
Non-profit (5042)
North Carolina (665)
Northern California (727)
Obesity (137)
Ohio (94)
Opinion (234)
Patents (68)
Pennsylvania (504)
People (63606)
Pharmaceutical (118)
Phase I (21595)
Phase II (30519)
Phase III (23058)
Pipeline (91)
Podcasts (75)
Postmarket research (3529)
Preclinical (9751)
Press Release (72)
Rare diseases (128)
Real estate (7358)
Recruiting (72)
Regulatory (25511)
Research institute (2631)
Resumes & cover letters (645)
South America (1640)
Southern California (678)
Startups (4268)
Texas (199)
United States (8080)
Vaccines (544)
Washington State (256)
Weight loss (137)
Date
Today (146)
Last 7 days (554)
Last 30 days (1756)
Last 365 days (38510)
2024 (26317)
2023 (42566)
2022 (53929)
2021 (58727)
2020 (57671)
2019 (51341)
2018 (39126)
2017 (37193)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36269)
2012 (38416)
2011 (38383)
2010 (39616)
822,655 Results for "bit bio".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
bit.bio Launches ioAstrocytes, Advancing How Scientists Can Model the Human Brain
bit.bio, the company coding human cells for novel cures and a pioneer in the field of synthetic biology, announces the launch of ioAstrocytes.
June 20, 2024
·
5 min read
Business
bit.bio Announced as Inaugural Partner of Ginkgo Bioworks’ New Technology Network
bit.bio, the company coding human cells for novel cures, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced bit.bio as an inaugural partner of the Ginkgo Technology Network.
February 28, 2024
·
9 min read
Genetown
bit.bio Announces First Project Within Multi-Year Collaboration Agreement with The Michael J. Fox Foundation (MJFF) to Generate Human Cell Products for Research and Drug Discovery in Parkinson’s disease
bit.bio, the company coding human cells for novel cures, announces the first project within a multi-year collaboration agreement with The Michael J. Fox Foundation for Parkinson’s Research to prioritise the development and delivery of a range of human cell products relevant to Parkinson’s disease.
March 5, 2024
·
5 min read
bit.bio further expands ioCells™️ range with early access launch of ioMotor Neurons™️ for research and drug discovery in diseases such as amyotrophic lateral sclerosis (ALS)
bit.bio, the company coding human cells for novel cures, has launched ioMotor Neurons as its 12th ioCells product this year.
December 6, 2023
·
5 min read
Business
Nobel Laureate Thomas Südhof and bit.bio CEO Mark Kotter to Lead Fireside Chat on Programming Human Cells at SynBioBeta
Südhof and Kotter’s fireside chat titled “Programming Human Cells: The Next Frontier of SynBio for Human Health” will explore some of the most profound questions in biology, including what determines a cell’s identity, and how can it be changed?
April 29, 2024
·
5 min read
Genetown
bit.bio Unveils Cell Therapy Pipeline, Including Lead Candidate for Acute Liver Failure, and Significantly Expands Scientific Advisory Board with Global Experts in Cell Therapy
bit.bio, the company coding human cells for novel cures, announced its cell therapy pipeline and declared its lead cell therapy candidate as it prepares to enter clinical development in 2025.
November 8, 2023
·
10 min read
Business
bit.bio Expands Board of Directors With Appointment of Distinguished Investor, Philanthropist, and Scientist
Weslie Janeway joins bit.bio board.
May 11, 2023
·
4 min read
Business
Synthego and bit.bio Expand Strategic Partnership to Build a Platform for the Development of Safer and More Efficient Genetic Engineering of Human Cells for Cell Therapies
Synthego and bit.bio announced a strategic partnership to build a platform centered on the implementation of synthetic circuitry in cells for therapeutic application.
August 24, 2023
·
4 min read
Genetown
bit.bio is Industrialising Human Cell Manufacturing, Unleashing the Potential of Synthetic Biology for Reproducible Research and Affordable Regenerative Medicines
bit.bio, a synthetic biology company focused on human cells, has achieved a milestone in the manufacture of human cells.
June 15, 2023
·
12 min read
Biotech Bay
Mekonos Announces Research Collaboration With bit.bio to Advance Cell Engineering
Mekonos, Inc. has announced a new research collaboration with bit.bio, a synthetic biology company providing human cells for research, drug discovery and cell therapy.
May 4, 2023
·
2 min read
1 of 82,266
Next
